OOIR: Observatory of International Research

Papers

(The H4-Index of Antiviral Research is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Editorial Board	365
Editorial Board	106
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination	99
Editorial Board	68
Editorial Board	67
Novel inhibitors of HSV-1 protease effective in vitro and in vivo	65
Corrigendum to “Crystal structure and cap binding analysis of the methyltransferase of langat virus” [Antivir. Res. 208 (2022) 105459]	65
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.	62
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies	57
A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN	51
Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice	42
Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs	38
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2	38
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study	38
Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells	37
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier	36
Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models	35
Berberine promotes K48-linked polyubiquitination of HNF4α, leading to the inhibition of HBV replication	35
A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy	35
A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies	35
Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response	34
Chemical-induced degradation of PreS2 mutant surface antigen via the induction of microautophagy	33
Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients	33
Conserved use of the sodium/bile acid cotransporter (NTCP) as an entry receptor by hepatitis B virus and domestic cat hepadnavirus	31
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals	30

Corrigendum to “The novel therapeutic target and inhibitory effects of PF-429242 against Zika virus infection” [Antivir. Res. vol 192 (2021) 1–13/105121]	30
Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections	30
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model	30
Editorial Board	29